scholarly journals Integrated space–frequency–time domain feature extraction for MEG-based Alzheimer’s disease classification

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Su Yang ◽  
Jose Miguel Sanchez Bornot ◽  
Ricardo Bruña Fernandez ◽  
Farzin Deravi ◽  
KongFatt Wong-Lin ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Time Domain ◽  
Recognition Performance ◽  
Binary Classification ◽  
Recognition Rate ◽  
Recognition System ◽  
Disease Classification ◽  
Machine Learning Techniques ◽  
Left Frontal Lobe

AbstractMagnetoencephalography (MEG) has been combined with machine learning techniques, to recognize the Alzheimer’s disease (AD), one of the most common forms of dementia. However, most of the previous studies are limited to binary classification and do not fully utilize the two available MEG modalities (extracted using magnetometer and gradiometer sensors). AD consists of several stages of progression, this study addresses this limitation by using both magnetometer and gradiometer data to discriminate between participants with AD, AD-related mild cognitive impairment (MCI), and healthy control (HC) participants in the form of a three-class classification problem. A series of wavelet-based biomarkers are developed and evaluated, which concurrently leverage the spatial, frequency and time domain characteristics of the signal. A bimodal recognition system based on an improved score-level fusion approach is proposed to reinforce interpretation of the brain activity captured by magnetometers and gradiometers. In this preliminary study, it was found that the markers derived from gradiometer tend to outperform the magnetometer-based markers. Interestingly, out of the total 10 regions of interest, left-frontal lobe demonstrates about 8% higher mean recognition rate than the second-best performing region (left temporal lobe) for AD/MCI/HC classification. Among the four types of markers proposed in this work, the spatial marker developed using wavelet coefficients provided the best recognition performance for the three-way classification. Overall, the proposed approach provides promising results for the potential of AD/MCI/HC three-way classification utilizing the bimodal MEG data.

scholarly journals Modular machine learning for Alzheimer's disease classification from retinal vasculature

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jianqiao Tian ◽  
Glenn Smith ◽  
Han Guo ◽  
Boya Liu ◽  
Zehua Pan ◽  
...  
Keyword(s):  
Machine Learning ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Classification Accuracy ◽  
Disease Classification ◽  
Machine Learning Techniques ◽  
Retinal Vasculature ◽  
Small Vessels ◽  
The Uk ◽  
Saliency Analysis

AbstractAlzheimer's disease is the leading cause of dementia. The long progression period in Alzheimer's disease provides a possibility for patients to get early treatment by having routine screenings. However, current clinical diagnostic imaging tools do not meet the specific requirements for screening procedures due to high cost and limited availability. In this work, we took the initiative to evaluate the retina, especially the retinal vasculature, as an alternative for conducting screenings for dementia patients caused by Alzheimer's disease. Highly modular machine learning techniques were employed throughout the whole pipeline. Utilizing data from the UK Biobank, the pipeline achieved an average classification accuracy of 82.44%. Besides the high classification accuracy, we also added a saliency analysis to strengthen this pipeline's interpretability. The saliency analysis indicated that within retinal images, small vessels carry more information for diagnosing Alzheimer's diseases, which aligns with related studies.

scholarly journals Alzheimer’s Disease Classification using Leung-Malik Filtered Bank Features and Weak Classifier

2019 ◽  
Vol 8 (3) ◽  
pp. 1956-1961
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Filter Bank ◽  
Binary Classification ◽  
Brain Mri ◽  
Texture Features ◽  
Disease Classification ◽  
Weak Classifier ◽  
Frame Work ◽  
Multi Class Classification

We propose a frame work to classify Brain MRI images in to Alzheimer’s Disease (AD), Cognitive Normal (CN) and Mild Cognitive impairments (MCI). We use 114No’s of T2 weighted MRI Volumes. We extracted relative texture features from Leung-Malik Filter bank, k means is used to generate Bag of Dictionary (BoD) from LM Filtered images. We performed binary classification and Multi class Classification using different Classifiers, Adaboost Classifier gives better performance both in binary and multi class classifications in comparison with other classifiers. Performance of proposed system is enhanced than compared to the existing techniques. It has Sensitivity for AD-CN 89.8, AD-MCI 78.82, AD-CN-MCI 77.77, Specificity for AD-CN79.22, AD-MCI 80.00, AD-CN-MCI 58.88, and positive prediction value for AD-CN 79.48, AD-MCI 83.75, AD-CN-MCI 68.47 and Accuracy AD-CN 84.24, AD-MCI 79.33, AD-CN-MCI 72.88.

scholarly journals A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer’s disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shaker El-Sappagh ◽  
Jose M. Alonso ◽  
S. M. Riazul Islam ◽  
Ahmad M. Sultan ◽  
Kyung Sup Kwak
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cross Validation ◽  
Disease Risk ◽  
Binary Classification ◽  
Fuzzy Rule ◽  
Large Set ◽  
Detection Model ◽  
Multi Class Classification ◽  
Clinical Measures

AbstractAlzheimer’s disease (AD) is the most common type of dementia. Its diagnosis and progression detection have been intensively studied. Nevertheless, research studies often have little effect on clinical practice mainly due to the following reasons: (1) Most studies depend mainly on a single modality, especially neuroimaging; (2) diagnosis and progression detection are usually studied separately as two independent problems; and (3) current studies concentrate mainly on optimizing the performance of complex machine learning models, while disregarding their explainability. As a result, physicians struggle to interpret these models, and feel it is hard to trust them. In this paper, we carefully develop an accurate and interpretable AD diagnosis and progression detection model. This model provides physicians with accurate decisions along with a set of explanations for every decision. Specifically, the model integrates 11 modalities of 1048 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) real-world dataset: 294 cognitively normal, 254 stable mild cognitive impairment (MCI), 232 progressive MCI, and 268 AD. It is actually a two-layer model with random forest (RF) as classifier algorithm. In the first layer, the model carries out a multi-class classification for the early diagnosis of AD patients. In the second layer, the model applies binary classification to detect possible MCI-to-AD progression within three years from a baseline diagnosis. The performance of the model is optimized with key markers selected from a large set of biological and clinical measures. Regarding explainability, we provide, for each layer, global and instance-based explanations of the RF classifier by using the SHapley Additive exPlanations (SHAP) feature attribution framework. In addition, we implement 22 explainers based on decision trees and fuzzy rule-based systems to provide complementary justifications for every RF decision in each layer. Furthermore, these explanations are represented in natural language form to help physicians understand the predictions. The designed model achieves a cross-validation accuracy of 93.95% and an F1-score of 93.94% in the first layer, while it achieves a cross-validation accuracy of 87.08% and an F1-Score of 87.09% in the second layer. The resulting system is not only accurate, but also trustworthy, accountable, and medically applicable, thanks to the provided explanations which are broadly consistent with each other and with the AD medical literature. The proposed system can help to enhance the clinical understanding of AD diagnosis and progression processes by providing detailed insights into the effect of different modalities on the disease risk.

Machine Learning Techniques for the Diagnosis of Alzheimer’s Disease

2020 ◽  
Vol 16 (1s) ◽  
pp. 1-35 ◽  
Author(s):  
M. Tanveer ◽  
B. Richhariya ◽  
R. U. Khan ◽  
A. H. Rashid ◽  
P. Khanna ◽  
...  
Keyword(s):  
Machine Learning ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Machine Learning Techniques ◽  
Learning Techniques

scholarly journals Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Shingo Tsuji ◽  
Takeshi Hase ◽  
Ayako Yachie-Kinoshita ◽  
Taiko Nishino ◽  
Samik Ghosh ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Deep Learning ◽  
Drug Target ◽  
Target Genes ◽  
Drug Repositioning ◽  
Therapeutic Targets ◽  
Machine Learning Techniques ◽  
Computational Framework ◽  
Novel Therapeutic

Abstract Background Identifying novel therapeutic targets is crucial for the successful development of drugs. However, the cost to experimentally identify therapeutic targets is huge and only approximately 400 genes are targets for FDA-approved drugs. As a result, it is inevitable to develop powerful computational tools that can identify potential novel therapeutic targets. Fortunately, the human protein-protein interaction network (PIN) could be a useful resource to achieve this objective. Methods In this study, we developed a deep learning-based computational framework that extracts low-dimensional representations of high-dimensional PIN data. Our computational framework uses latent features and state-of-the-art machine learning techniques to infer potential drug target genes. Results We applied our computational framework to prioritize novel putative target genes for Alzheimer’s disease and successfully identified key genes that may serve as novel therapeutic targets (e.g., DLG4, EGFR, RAC1, SYK, PTK2B, SOCS1). Furthermore, based on these putative targets, we could infer repositionable candidate-compounds for the disease (e.g., tamoxifen, bosutinib, and dasatinib). Conclusions Our deep learning-based computational framework could be a powerful tool to efficiently prioritize new therapeutic targets and enhance the drug repositioning strategy.

Lightweight deep residual network for alzheimer’s disease classification using sMRI slices

2021 ◽  
pp. 1-9
Author(s):  
Yanteng Zhang ◽  
Qizhi Teng ◽  
Linbo Qing ◽  
Yan Liu ◽  
Xiaohai He
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Deep Learning ◽  
Computational Cost ◽  
Disease Classification ◽  
Learning Networks ◽  
Feature Maps ◽  
Medical Field ◽  
Widespread Application ◽  
Healthy Control

Alzheimer’s disease (AD) is a degenerative brain disease and the most common cause of dementia. In recent years, with the widespread application of artificial intelligence in the medical field, various deep learning-based methods have been applied for AD detection using sMRI images. Many of these networks achieved AD vs HC (Healthy Control) classification accuracy of up to 90%but with a large number of computational parameters and floating point operations (FLOPs). In this paper, we adopt a novel ghost module, which uses a series of cheap operations of linear transformation to generate more feature maps, embedded into our designed ResNet architecture for task of AD vs HC classification. According to experiments on the OASIS dataset, our lightweight network achieves an optimistic accuracy of 97.92%and its total parameters are dozens of times smaller than state-of-the-art deep learning networks. Our proposed AD classification network achieves better performance while the computational cost is reduced significantly.

Sign in / Sign up

Export Citation Format

Share Document